The levels of IL-17 and IL-23 in CSF and serum have been found to be significantly increased in ALS patients compared to patients with non-inflammatory neurodegenerative diseases (Rentzos et al., 2010). This evidence concerns the gene IL17A and neurodegenerative disease.